Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-Breast01
PACTR202606480432847Phase 2Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of izalontamab brengitecan in triple-negative breast cancer (TNBC) and breast cancer, sponsored by Bristol Myers Squibb. Primary endpoint: Progression-Free Survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on PACTR202606480432847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606480432847.